On September 22, 2026, the U.S. Environmental Protection Agency and the Department of Health and Human Services announced a Memorandum of Understanding intended to strengthen scientific coordination in EPA’s pesticide registration review for glyphosate. The Glyphosate Review therefore gained broader federal scientific input, but the MOU did not itself decide the pesticide’s regulatory status or give HHS independent decision-making power under FIFRA.
The practical value of the partnership depends on how EPA uses the added scientific exchange, what new or existing evidence can support, and whether unresolved questions about formulations, exposure pathways, and health endpoints can be addressed within EPA’s review schedule. For readers exploring federal science reporting on related subjects, the insights available through the Harvard Science Review provide valuable context from a connected publication network.
What The EPA-HHS Glyphosate Review MOU Changes
Glyphosate Review Scope And Agency Roles
The most direct benefit is procedural: EPA and HHS created a formal structure for scientific coordination. EPA said the MOU establishes a joint technical working group with experts from EPA’s Office of Pesticide Programs and HHS agencies, including NIEHS, NTP, NCI, NIOSH, CDC’s NCEH, and FDA. The working group is intended to identify research gaps, exchange data, and align work with EPA’s registration review schedule, according to the EPA announcement.
That structure may reduce the risk that relevant federal expertise remains separated across agencies. Cancer evaluation, occupational exposure, toxicology, public health surveillance, and food-related exposure are not identical disciplines. A technical working group can help EPA compare different evidence streams before it updates its human health risk assessment.
The limitation is just as clear. Coordination is not the same as a new statutory test. The MOU does not transfer FIFRA authority from EPA to HHS. EPA remains the agency responsible for pesticide registration review decisions. HHS agencies can contribute scientific expertise, but the final regulatory analysis still has to fit EPA’s governing framework.
Transparency Commitments And Public Materials
EPA and HHS also committed to making working-group materials public on a rolling basis through Docket EPA-HQ-OPP-2009-0361, while protecting confidential business information and other restricted material. That type of staged release can make it easier for external reviewers to see what evidence is being considered before final decisions are issued.
Transparency, however, is not the same as certainty. Public release of materials may improve visibility into the process, but it cannot resolve evidence gaps by itself. If the underlying literature lacks recent epidemiological data for certain exposure patterns or populations, a public docket can show that limitation rather than remove it.
Evidence Gains And Open Questions
Formulations, Exposure, And Effects
EPA has said the updated human health risk assessment will address exposure through more formulations, including surfactants, as well as dietary exposure, occupational exposure, cancer, genotoxicity, and reproductive or developmental effects. That is significant because glyphosate products are not used only as isolated active-ingredient concepts in a laboratory setting. Real-world exposure can involve formulated products and different use conditions.
For Glyphosate Review, this broader scope is a benefit if it leads to clearer separation between what is known about glyphosate as an active ingredient and what is known about particular commercial formulations. It may also help EPA evaluate occupational contexts, including workers who may experience different exposure conditions than the general population.
The evidence challenge is that expanding the questions can expose areas where the available data are thinner. The research record cited for this topic indicates concerns about limited up-to-date epidemiological data, especially for low-dose exposure, surfactant formulations, and vulnerable populations. A wider review scope is useful only to the extent that the available studies are relevant, reliable, and sufficient for the specific question being asked.
Open Literature And Public Input
EPA released an open literature search on August 25, 2026, covering peer-reviewed studies since its previous open review in 2017. The research notes indicate that the document is intended to feed into EPA’s updated human health risk assessment. EPA then extended the public comment period on September 25, 2026, moving the deadline from September 24, 2026, to November 23, 2026.
That extension matters because the review affects many parties with different kinds of evidence: registrants, agricultural users, public health researchers, worker-safety specialists, food-system participants, and advocacy organizations. More time can improve the opportunity to submit studies and technical comments. It does not guarantee that submitted material will change EPA’s conclusions, because EPA must still determine relevance, quality, and weight of evidence.
Operational Effects For Industrial Stakeholders
Chemical Use Records And Exposure Context
For industrial buyers and compliance teams, the MOU should not be read as an immediate change in product legality, purchasing status, or handling requirements. It is a scientific coordination step inside EPA’s registration review process. Any operational decision should therefore remain tied to current labels, safety data sheets, supplier documentation, contractual obligations, and applicable federal and state requirements.
At the same time, procurement teams should track the review because it may shape future restrictions, label language, documentation expectations, or supply planning. Similar evidence-management issues appear in other chemical programs; a related discussion of EPA risk evaluations and supply chain efficiency explains why buyers should separate active regulatory review from a final control requirement.
A defensible internal process should distinguish between scientific uncertainty and regulatory status. A product can remain available while a review is active, but that does not mean the review lacks significance. Conversely, a new interagency partnership does not mean a hazard conclusion has already changed.
What The MOU Cannot Do For Buyers
The MOU cannot substitute for site-specific compliance review. It does not answer whether a particular facility’s use pattern, formulation, application method, worker protection program, or waste-management practice is adequate. Those questions require product-specific and site-specific evaluation by qualified personnel.
Buyers should also avoid treating the partnership as a forecast of a single outcome. EPA’s updated assessment may confirm some prior positions, revise parts of the analysis, identify uncertainties, or lead to risk-management changes. The available research notes do not support assuming any one of those results before EPA publishes its updated analysis.
Limits Of The EPA-HHS Partnership
Authority Remains With EPA
The central limitation is legal authority. HHS expertise may broaden the evidence review, but EPA retains pesticide registration decision-making authority under FIFRA. That means the MOU can improve the scientific record and interagency communication without changing the agency that makes the regulatory decision.
This distinction matters for public expectations. A partnership with public-health agencies may be read by some observers as a sign that EPA is reopening every question from the beginning. The more cautious reading is that EPA is strengthening the record for an ongoing registration review, not creating a separate HHS-led approval system.
Timing, Evidence Gaps, And Legal Context
The timing question remains unsettled. EPA has anticipated completion of the updated human health risk assessment in late 2026, with a public webinar to follow in early 2027. Advocacy organizations have questioned whether the partnership can produce meaningful new evidence about commercial formulations within that period. The Center for Food Safety welcomed the MOU while warning that work on commercial formulations’ health impacts may take years to bear fruit, in its glyphosate statement.
The review also follows prior legal pressure. The research record for this topic states that, in 2022, the Ninth Circuit vacated the human-health portion of EPA’s earlier Interim Decision on glyphosate, finding that it lacked sufficient support. That history raises the stakes for documentation, reasoning, and evidence quality in the updated assessment.
None of these limits mean the partnership is without value. They mean the benefits are mainly procedural and evidentiary at this stage. The partnership can help organize federal expertise, expand the questions under review, and improve public visibility. It cannot, by itself, fill every data gap or settle contested interpretations of mixed scientific evidence.
EPA-HHS Partnership On Glyphosate Review
The EPA-HHS partnership on Glyphosate Review is best understood as a stronger review process rather than a final scientific or regulatory answer. Its benefits are clear: wider federal expertise, a defined working group, attention to formulations and exposure pathways, public materials, and an extended opportunity for public input.
Its limitations are also material. EPA remains the decision-maker under FIFRA, the schedule may constrain how much new work can be completed before early 2027 public discussion, and existing literature gaps may continue to limit certainty for some exposure scenarios. For industrial and compliance teams, the prudent response is to monitor the docket, maintain current product controls, and avoid treating the MOU as either a ban signal or a safety clearance.